Enveric Biosciences, Inc. · NASDAQ:ENVB

Enveric Biosciences — Investor Presentation (January 2024)

21 slides from Enveric Biosciences's investor presentation, January 2024

  1. Slide 1: Corporate Presentation Q1 2024

    :ENVB CORPORATE PRESENTATION Q1 2024 Enveric.com

  2. Slide 2: Disclaimer

    Dis c la im e r No Offe r o r S o lic it a t io n This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the s o lic ita tio n o f a n o ffe r to b uy a ny s e c uritie s o r a s o lic ita tio n o f a ny vo te o r a p p ro va l. It d

  3. Slide 3: Next Generation Mental Health

    Next Generation TM Mental Health

  4. Slide 4: Mental Health Epidemic

    Me n t a l He a lt h Ep id e m ic WIDESPREAD HIGH DISABILITY 1 in 4 e xp e rie nce s a me nta l illne ss in a ny Me nta l illne ss a nd sub sta nce use g ive n ye a r d isord e rs a re the le a d ing ca use s of d isa b ility LOW EFFICACY DIMINISHED LONGEVITY People with severe mental health 40% con

  5. Slide 5: Neuroplastogens: A new Class of Drugs

    :ENVB Ne u ro p la s t o g e n s : A n e w Cla s s o f Dru g s Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate Neuropsychiatric Illness: Reduced neural neuroplasticity in the PFC, whic

  6. Slide 6: Our Portfolio of Neuroplastogen Molecules

    PsybraryTM Ou r Po rt fo lio o f O F Ne u ro p la s t o g e n Mo le c u le s • The PsybraryTM : Our library of 500+ potential neuroplastogen drug candidates F F • We combined synthetic biology HO and chemistry technologies to create a highly diverse portfolio for F CI drug discovery • Molecules are

  7. Slide 7: Distinct Neuroplastogen Treatment Paradigms

    :ENVB Dis t in c t Ne u ro p la s t o g e n Tre a t m e n t Pa ra d ig m s In Clin ic Pre s c rip t io n Mo d e l • High dose • Moderate dose • Clinical setting • Prescription model • One course of therapy potentially • Taken regularly provides benefit for months • Minimal side effects and reduced •

  8. Slide 8: Pipeline Programs

    :ENVB Pip e lin e Pro g ra m s PROGRAM INDICATION PERFORMANCE GOALS DISCOVERY PRE-CLINICAL PHASE I NEXT MILESTONE 5HT2AR ligand, brain- In Clin ic : An xie t y targeted, faster-acting, EB- 0 0 2 shorter duration, reduced Initiate FIH in Australia GI upset 5HT2AR ligand, sub-clinical Pre s c rip t io

  9. Slide 9: In Clinic Program: EB-002

    :ENVB In Clin ic Pro g ra m : EB- 0 0 2 Synopsis of Target Benefits • Altered metabolic and pharmacokinetic properties relative to psilocybin to achieve improved risk/benefit profile • Flexible delivery route – potential for oral, intra-nasal, buccal or intravenous route for ⚬ Faster access to targe

  10. Slide 10: EB-002 Development

    :ENVB EB- 0 0 2 De v e lo p m e n t Developed an improved Established Enveric Agreement with Repeat dose toxicology studies have been formulation of EB-002 Therapeutics Pty. Ltd., an Avance Clinical, an completed. Cardiac, respiratory, CNS safety designed to enhance the Australia-based Australia-bas

  11. Slide 11: EB-002 Development

    :ENVB EB- 0 0 2 De v e lo p m e n t • GLP toxicology studies in orally dosed rats and dogs are in advanced stages, with all in-life activities completed. • A broad margin of safety and tolerability is maintained with repeat dose testing. • Complete analysis and final reporting are expected by the en

  12. Slide 12: Anxiety Market: New Treatments Needed

    An xie t y Ma rk e t : Ne w $ 16 .3 B Ma r k e t Tre a t m e n t s Ne e d e d USD Market • Anxiety disorders are among the most common CNS Disorders, by 2029 Source: Data Bridge ranking second. • Anxiety disorders are chronic conditions that remain poorly controlled despite available treatments. Pe

  13. Slide 13: Prescription Model Program: EB-003

    Pre s c rip t io n Mo d e l Pro g ra m : EB- 0 0 3 Synopsis of Target Benefits • Reduced hallucination profile • Improved cardiac safety • Orally bioavailable, chronic administration • Treatment in clinic not required • Drug intended to be prescribed for regular maintenance and taken at times and in

  14. Slide 14: Neuropsychiatric Market Rapidly Growing

    Ne u ro p s y c h ia t ric Ma rk e t The global behavioral Ma r k e t drug market size is Ra p id ly Gro w in g expected to reach • Neuropsychiatric disorders continue to be a tremendous unmet need with limited innovation. • The last FDA-approved drug to treat Neurpsychiatric disorders was Esketamin

  15. Slide 15: Intellectual Property

    In t e lle c t u a l Pro p e rt y :ENVB PsybraryTM: Portfolio of 500+ drug candidates Patents ⚬ EB-002: ⚬ US Patent 11,707,447; and US Patent 11,845,726; one more US application and one PCT application – compositions of numerous EB-002 molecules ⚬ Prodrug molecules other than EB-002 ⚬ ⚬ US Patent 11

  16. Slide 16: Potential for Strategic Drug Development Deals

    Po t e n t ia l fo r St ra t e g ic Dru g De v e lo p m e n t De a ls Example Partnership: Upfront Cash and/or Equity Purchase Milestone Payments Collaboration and License Agreement Partners: Biogen, Sage Jurisdiction: Global Products: Sage-217, Sage-324 Stage: Phase 3 Indications: PPD, MDD, essenti

  17. Slide 17: Competitive Landscape

    Company Program Status Ticker Market Cap Progress Gen 2 Pre-Clinical Enveric Public NASDAQ:ENVB $3.06M Biosciences Gen 3 Pre-Clinical Gen 1 Phase 3 Compass Public NASDAQ:CMPS $594.82M Pathways Gen 2 Pre-Clinical Gen 2 Phase 2 Cybin Inc. Public NYSE:CYBN $162.61M Gen 3 Pre-Clinical $73.6 Total fundin

  18. Slide 18: Management

    Ma n a g e m e n t Management Team Board of Directors Scientific Advisors Joseph Tucker, Ph.D. Michael D. Webb Maurizio Fava, M.D, CEO & Director Board Chair Scientific Advisor Stephen M. Stahl, M.D., George Kegler Scientific Advisor Director, Chair of the Audit Committee Kevin Coveney, CPA Sheila D

  19. Slide 19: Value Inflection Points

    Va lu e In fle c t io n Po in t s EB-002 File HREC for EB-002 in Australia First patient dosed in Phase 1 clinical trial – EB-002 Positive results from initial Phase 1 clinical trial for EB-002 File IND for EB=002 in US EB-003 Additional Notices of Allowance for EB-003 Manufacturing- optimized formu

  20. Slide 20: The Future of Neuroplastogen Medicine

    Th e Fu t u re o f Ne u ro p la s t o g e n Me d ic in e Pipeline provides multiple shots on goal • Patented molecules can address multiple psychological indications Strong IP Portfolio • Five patents and nine patent Notices of Allowance with 10+ more anticipated • Large number of molecules expected

  21. Slide 21: Enveric Biosciences

    Nasdag :ENVB Mental Health™ BIOS CIENCES Enveric.com

Enveric Biosciences — Investor Presentation (January 2024) on 6ix